In the rapidly changing field of medicine, effective communications are essential to ensuring that innovations are cascaded out across the health system.
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh